April 15, 2021
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030
- Grifols’ new commitment of international units (IU) of blood clotting factors for humanitarian aid through the WFH from 2022 to 2030 will more than double its IU donations since 2014, reaching 440 million IU
- The company’s blood clotting factor donations consist principally of plasma-derived Factor VIII and Factor IX, contributing to the treatment of the approximately 75% of hemophilia patients who lack access to adequate care
Barcelona, Spain, April 15, 2021 – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people’s health and well-being, today announced that it will donate a minimum of 240 million international units (IU) of blood clotting factor medicines (Factor VIII and Factor IX) to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next eight years, from 2022 to 2030.
This contribution extends the company’s commitment that began in 2014 and will bring its total humanitarian aid commitment to more than 440M IU of Factor VIII and Factor IX over 16 years.
For more than two decades, Grifols has been a proud supporter of the WFH and its efforts to improve access to treatment of bleeding disorders around the world. The extended partnership with WFH reaffirms Grifols’ commitment to the global hemophilia community and accounts for the company’s most significant contribution to the WFH Humanitarian Aid Program to date.
According to the WFH, the donation of the additional 240 million IU will secure a projected average of 10,300 doses to treat approximately 3,000 patients per year through 2030 in developing countries worldwide where access to adequate treatment is often lacking or absent.
“Helping to address global health inequities is an essential part of fulfilling our corporate mission,” said Victor Grifols Deu, co-CEO of Grifols.
“We consider product donations to the World Federation of Hemophilia to be an ethical imperative for our company rather than a simple choice,” added Raimon Grifols, co-CEO of Grifols.
Grifols produces plasma-derived medicines to treat chronic rare diseases such as hemophilia and also develops solutions for the diagnoses of bleeding disorders. In 2020, Grifols extended an agreement with the WFH to support donations of products manufactured outside of the U.S. as well, expanding its ability to reach patients worldwide.
“Since its creation in 1996, the WFH Humanitarian Aid Program has benefitted almost 100,000 people in over 100 countries. When patients are able to receive consistent and reliable access to treatment and care, they have hope for a better quality of life,” said Alain Baumann, CEO of WFH.
An estimated 400,000 people around the world have severe hemophilia, yet only 25% receive adequate treatment. Grifols’ donation also supports the second decade of the WFH Global Alliance for Progress (GAP) program aimed at increasing the number of patients diagnosed and treated for bleeding disorders, particularly in the world’s most impoverished countries.
For more information about WFH, hemophilia and other bleeding disorders go to http://www.wfh.org/.